The combination of durvalumab plus chemotherapy is associated with better patient-reported outcomes than chemotherapy alone, suggests data from the CASPIAN trial comprising treatment-naïve individuals with extensive-stage small-cell lung cancer.
A phase II trial shows that the intravenous prodrug fosnetupitant in combination with palonosetron reduces chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Among the potential active treatment options for prostate cancer, external‐beam radiotherapy alone results in the best preservation of sexual function up to 2 years after treatment, population-based study data show.
Switching palliative radiation for high-dose radical hemi-thoracic radiotherapy significantly increases 2-year overall survival among patients with a new diagnosis of malignant pleural mesothelioma, delegates were told at the ESTRO 38 meeting in Milan, Italy.
Hypofractionated radiotherapy is similar to conventional radiotherapy when it comes to health-related quality of life in men with low-risk prostate cancer, according to the RTOG 0415 phase III randomized controlled trial.
Men with nonmetastatic, castration-resistant prostate cancer receiving enzalutamide maintain their low baseline pain levels and prostate cancer symptom burden and report high health-related quality of life, indicates a patient-reported outcomes analysis of the phase III PROSPER study.
Patients with previously untreated intermediate- or poor-risk advanced renal cell carcinoma derive greater health-related quality of life benefits from nivolumab plus ipilimumab than from sunitinib, CheckMate 214 data show.
Hashim Ahmed takes us through the COMPARE study – presented at NCRI 2018 – which showed that men with localized prostate cancer are willing to make accept lower survival odds for a better quality of life. He outlines the key findings, the implications of the results for physicians, and the next steps for research (5:36).
Men with a new diagnosis of nonmetastatic prostate cancer say they would accept small reductions in survival odds if that meant fewer side effects and an improved quality of life, suggests the COMPARE study.
Two independent studies of older patients receiving initial chemotherapy for metastatic breast cancer or non-small-cell lung cancer have found that the risk for hospitalization or death may be predicted by the cytotoxic regimen used.
Progression-free survival should not be used as a surrogate marker for health-related quality of life as there is no correlation between them, results of a systematic review and quantitative analysis of randomized clinical trials show.
Patients who undergo video-assisted thoracoscopic surgery for stage I non-small-cell lung cancer are less likely to become long-term opioid users than their counterparts undergoing the conventional open procedure, findings suggest.
Men with high-risk nonmetastatic castration-resistant prostate cancer do not report a deterioration in health-related quality of life when androgen deprivation therapy is supplemented with apalutamide, indicate SPARTAN trial results.